[go: up one dir, main page]

BRPI0506470A - produtos farmacêuticos esteroidal direcionado a helix 12, incluindo composto molecular da fórmula ou sal do mesmo; composição farmacêutica e método de tratamento - Google Patents

produtos farmacêuticos esteroidal direcionado a helix 12, incluindo composto molecular da fórmula ou sal do mesmo; composição farmacêutica e método de tratamento

Info

Publication number
BRPI0506470A
BRPI0506470A BRPI0506470-8A BRPI0506470A BRPI0506470A BR PI0506470 A BRPI0506470 A BR PI0506470A BR PI0506470 A BRPI0506470 A BR PI0506470A BR PI0506470 A BRPI0506470 A BR PI0506470A
Authority
BR
Brazil
Prior art keywords
helix
salt
treatment method
pharmaceutical composition
molecular compound
Prior art date
Application number
BRPI0506470-8A
Other languages
English (en)
Inventor
Fernand Labrie
Shankar Singh
Sylvain Gauthier
Yvon Frechette
Sylvain Chenard
Rock Breton
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of BRPI0506470A publication Critical patent/BRPI0506470A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

"PRODUTOS FARMACêUTICOS ESTEROIDAL DIRECIONADO A HELIX 12, INCLUINDO COMPOSTO MOLECULAR DA FóRMULA OU SAL DO MESMO; COMPOSIçãO FARMACêUTICA E MéTODO DE TRATAMENTO". Compostos possuindo a estrutura ou seus sais são usados para o tratamento ou redução da probabilidade de adquirir doenças que dependem de andrógeno, tais como, câncer de próstata, hiperplasia prostática benigna, sindrome ovariana policística, acne, hirsutismo, seborréia, alopecia androgênica e males da calvície. Eles podem ser formulados juntos com diluentes ou condutores aceitáveis farmacêuticamente ou por outro lado feitos em qualquer forma de dosagem farmacêutica. Alguns destes compostos possuindo tecido específico de atividade antiandrogênica podem ser usados para tratar ou reduzir o risco do desenvolvimento das doenças referentes à perda da estimulação androgênica. Combinações com outros agentes farmacêuticos ativos, são também revelados.
BRPI0506470-8A 2004-01-07 2005-01-06 produtos farmacêuticos esteroidal direcionado a helix 12, incluindo composto molecular da fórmula ou sal do mesmo; composição farmacêutica e método de tratamento BRPI0506470A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53512104P 2004-01-07 2004-01-07
PCT/CA2005/000011 WO2005066194A1 (en) 2004-01-07 2005-01-06 Helix 12 directed steroidal pharmaceutical products

Publications (1)

Publication Number Publication Date
BRPI0506470A true BRPI0506470A (pt) 2007-02-21

Family

ID=34749018

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506470-8A BRPI0506470A (pt) 2004-01-07 2005-01-06 produtos farmacêuticos esteroidal direcionado a helix 12, incluindo composto molecular da fórmula ou sal do mesmo; composição farmacêutica e método de tratamento

Country Status (15)

Country Link
US (1) US9090651B2 (pt)
EP (1) EP1704161A4 (pt)
JP (1) JP4866740B2 (pt)
KR (2) KR20130124576A (pt)
CN (2) CN1930181A (pt)
AU (2) AU2005203922A1 (pt)
BR (1) BRPI0506470A (pt)
CA (1) CA2551737C (pt)
IL (1) IL176538A0 (pt)
MY (1) MY157898A (pt)
NO (1) NO20063564L (pt)
RU (1) RU2397176C2 (pt)
TW (1) TWI383993B (pt)
WO (1) WO2005066194A1 (pt)
ZA (1) ZA200605242B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130124576A (ko) 2004-01-07 2013-11-14 앙도르쉐르슈 인코포레이티드 헬릭스 12 배향형 스테로이드계 약학 제품
RS20070166A (sr) 2004-10-20 2008-09-29 Endorecherche Inc., Prekursori seksualnih steroida sami ili u kombinaciji sa selektivnim modulatorom estrogenskog receptora i/ili sa inhibitorom cgmp fosfodiesteraze tipa 5 za prevenciju ili tretman isušenosti vaginalne sluzokože i seksualne disfunkcije kod žena u postmenopauzi
GB0428128D0 (en) * 2004-12-22 2005-01-26 Avecia Ltd Process
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CA2716320C (en) 2008-02-22 2014-01-28 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) * 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009142699A1 (en) * 2008-05-19 2009-11-26 The Procter & Gamble Company Treatment of heart failure in women
GB2461037A (en) * 2008-06-17 2009-12-23 Elias Bouras A method of treating alopecia using a composition comprising a cardiac glycoside
JP5711724B2 (ja) 2009-04-15 2015-05-07 リサーチ・トライアングル・インスティチュート モノアミン再取り込み阻害剤
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
EP3106159A1 (en) 2010-05-12 2016-12-21 Radius Health, Inc. Therapeutic regimens
CA2799653A1 (en) 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
JP5965909B2 (ja) 2010-09-28 2016-08-10 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
CN102746360B (zh) * 2012-06-19 2014-07-02 广西民族大学 四种喜树碱-甾体缀合物的合成及其应用
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
CN105237606B (zh) * 2014-07-11 2018-08-24 上海创诺制药有限公司 一种用于合成去氧孕烯的中间体及其制备方法和应用
CN105237605B (zh) * 2014-07-11 2019-01-25 上海迪赛诺生物医药有限公司 一种用于合成孕二烯酮的中间体及其制备方法和应用
CA2984357A1 (en) 2015-04-29 2016-11-03 Radius Pharmaceuticals, Inc. Methods for treating cancer
CA3027563C (en) 2016-06-22 2024-07-02 Ellipses Pharma Ltd AR+ METHODS FOR BREAST CANCER TREATMENT
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
CN108822175B (zh) * 2018-04-26 2021-01-05 昆明理工大学 3,16-雄甾烯二酮类化合物及其应用
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
CN119390714A (zh) 2019-02-12 2025-02-07 雷迪厄斯制药公司 方法和化合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
EP0254341B1 (en) * 1986-07-23 1990-01-03 Akzo N.V. Novel 18-phenyloestrane derivatives
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
WO1995018821A2 (en) * 1994-01-06 1995-07-13 Sri International Novel antiandrogenic agents and related pharmaceutical compositions and methods of use
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
WO1999046279A2 (en) 1998-03-11 1999-09-16 Endorecherche, Inc. INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
BR0111298A (pt) 2000-06-28 2005-05-10 Bristol Myers Squibb Co Moduladores seletivos dos receptores de andrógenos e métodos para identificação, projeto e uso dos mesmos
AU2001267904A1 (en) * 2000-06-30 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Novel antiandrogenic agent
TWI329108B (en) 2001-09-06 2010-08-21 Schering Corp 17-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE60309667D1 (de) * 2002-02-15 2006-12-28 Endorech Inc Biphenylderivate und ihre verwendung als antiandrogene
PL372920A1 (en) * 2002-03-13 2005-08-08 Merck & Co,Inc. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
AU2003223754B2 (en) * 2002-04-30 2007-08-16 Merck Sharp & Dohme Corp. 4-azasteroid derivatives as androgen receptor modulators
KR20130124576A (ko) 2004-01-07 2013-11-14 앙도르쉐르슈 인코포레이티드 헬릭스 12 배향형 스테로이드계 약학 제품
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators

Also Published As

Publication number Publication date
US9090651B2 (en) 2015-07-28
NO20063564L (no) 2006-10-09
TW200530264A (en) 2005-09-16
EP1704161A4 (en) 2011-06-08
US20050250749A1 (en) 2005-11-10
CN102358750B (zh) 2015-11-25
KR20130124576A (ko) 2013-11-14
CA2551737A1 (en) 2005-07-21
HK1167657A1 (zh) 2012-12-07
TWI383993B (zh) 2013-02-01
MY157898A (en) 2016-08-15
CN102358750A (zh) 2012-02-22
ZA200605242B (en) 2007-10-31
CN1930181A (zh) 2007-03-14
AU2009202038A2 (en) 2009-08-06
AU2009202038A1 (en) 2009-06-11
WO2005066194A1 (en) 2005-07-21
RU2397176C2 (ru) 2010-08-20
AU2005203922A1 (en) 2005-07-21
KR20070003851A (ko) 2007-01-05
JP2007519635A (ja) 2007-07-19
RU2006128574A (ru) 2008-02-20
EP1704161A1 (en) 2006-09-27
KR101536701B1 (ko) 2015-07-14
CA2551737C (en) 2009-11-10
JP4866740B2 (ja) 2012-02-01
IL176538A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
BRPI0506470A (pt) produtos farmacêuticos esteroidal direcionado a helix 12, incluindo composto molecular da fórmula ou sal do mesmo; composição farmacêutica e método de tratamento
BRPI0611828B8 (pt) compostos antiandrogênios não-esteroidais direcionados à hélice 12 e composição farmacêutica compreendendo os referidos compostos
Singh et al. Androgen receptor antagonists (antiandrogens) structure-activity relationships
BR9908592A (pt) Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
Stoliar et al. SCH 13521 in the treatment of advanced carcinoma of the prostate
BR9913903A (pt) Composto, método para tratar ou impedir um estado doentio, e, composição farmacêutica
PE15095A1 (es) Derivado de androstenona
BRPI0417158A (pt) composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença
PT939627E (pt) Pentafluorobenzenossulfonamidas e analogos
DE69034035D1 (de) Methode zur behandlung androgenbedingter krankheiten
PT1005453E (pt) Compostos de benzeno substituido como agentes de reducao antiproliferativa
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
BR0015911A (pt) Derivados de benzoimidazole úteis como agentes antiproliferativos
DE60213404D1 (de) Verwendung von sulodexid zur behandlung von reizdarm
AR021757A1 (es) Metodo para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona, inhibir la actividadde la 3alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana, para determinar la eficacia de un inhibidor putativo de la conversion de 4-androsten-3
BR0312845A (pt) Tetratiomolibdato de tetrapropilamÈnio e compostos relacionados para terapias antiangiogênicas
Brodie et al. Aromatase inhibitors and their potential clinical significance
BR0008437A (pt) Inibidores esteróides de sulfatase e métodos parafabricação e uso dos mesmos
ES2300323T3 (es) Quimioterapia combinada.
MXPA01013460A (es) Formulaciones topicas que comprenden agentes de penetracion de la piel y uso de las mismas.
NZ327041A (en) 17-beta-cyclopropyl(amino/oxy) 4-aza steriods as active inhibitors of testosterone 5-alpha-reductase and C17-20-lyase
Fujimoto et al. Enhancement of hyperthermochemotherapy for human gastric cancer in nude mice by thermosensitization with nitroimidazoles
BRPI0514187A (pt) composto, e, droga preventiva ou uma droga terapêutica
Gohil et al. Aromatase inhibitors: A safer approach for the treatment of breast cancer
D'Alessio et al. Synthesis and in vitro evaluation of novel aromatase inhibitors

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]